Neurocrine's total assets for Q2 2025 were $3.89B, an increase of 5.48% from the previous quarter. NBIX total liabilities were $1.20B for the fiscal quarter, a 3.78% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.